Q2 Solutions operates one of the world’s largest and most respected bioanalytical services laboratory networks. We represent a leading clinical trial laboratory services organization with bioanalytical, genomics, vaccines, flow cytometry, anatomic pathology, immunoassay, companion diagnostics and central laboratory services with secure, enterprise-wide biospecimen and consent management solutions. Recognizing that a clinical assay must be reliable over a period of years, Q2 Solutions benchmarks all projects using a rigorous bioanalytical method development strategy that includes a common set of SOPs, statistical analysis, and science writing support.
From in vitro ADME screening and discovery and development metabolite identification to DMPK services and regulatory validation, we can help you navigate your large-scale clinical study. Our integrated drug metabolism solutions include high-throughput screening assays, human clearance predictions, drug-drug interaction risk assessments and metabolite profiling to support clinical safety. In addition to the services listed below, we can also provide bundled services for discovery and regulatory-phase packages to enable decision-making in early discovery through IND and beyond.
Bioanalytical/Pharmacokinetics Services | |
---|---|
Discovery Phase Bioanalysis by LC-MS/MS | Details |
Tiered bioanalysis service available | Levels 0 – 3 (all non-regulated) |
Bioanalytical with optional Pharmacokinetic Analysis: Plasma, Tissues | Species selectable, non-compartmental analysis |
Bioanalytical with optional Pharmacokinetic Analysis: Dried Blood Spot | Species selectable, non-compartmental analysis |
In Vitro ADME Services | |
---|---|
High-Throughput Screening Assays | Details |
Solubility/Permeability Assays: | |
|
10 μM to 100 μM in buffer |
|
MDCK (wild type), MDCK-II cell lines |
|
Pre-coated PAMPA plate system |
Metabolic Stability Assays: | |
|
Hepatocytes or microsomes; Species selectable |
|
Hepatocytes or microsome; Species selectable |
|
Species selectable |
Inhibition Assays (enzyme): | |
|
Single concentration, P450 selectable (up to seven) |
P450 Inhibition: Reversible IC50 | Multiple concentrations, P450 selectable (up to seven) |
|
Single concentration, CYP3A |
|
CYP3A, CYP2B6, CYP2C8, CYP2C9, CYP2C19 |
|
CYP3A or CYP3A4, 2D6 and 2C9 cocktail assays |
Inhibition Assays (transporter): | |
|
Vesicles |
Reaction Phenotyping Assays: | |
|
Microsomes with inhibitors for CYP2C9, CYP2D6, CYP3A |
Other Assays: | |
|
Equilibrium dialysis HTDialysis or RED devise; Species selectable |
|
Species Selectable |
Bundled Tier 1 Screening Assays: | |
|
Human liver microsomes, MDCK, CYPs 2C9, 2D6, 3A in cocktail |
Late Stage Discovery to Regulatory Phase Assays | Details |
Metabolic Stability Assays: | |
|
Hepatocytes and microsomes; Species selectable (±ABT optional) |
|
Microsomes (liver, intestine, kidney); Species selectable (±BSA) |
|
Hepatocyte coculture systems (HµREL); Species selectable |
Inhibition Assays (enzyme): | |
|
CYP2C9, CYP2D6, CYP3A; combined reversible and TDI inhibition model |
|
Definitive IC50 for up to 7 P450s/8 assays |
|
Definitive Ki for selected P450s |
|
IC50 shift following 30 min pre-incubation (part of reversible inhibition IC50 assay) |
|
CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A; kinact / KI and CLinact |
|
Metabolic intermediate (MI) complex formation, CYP3A4 |
|
UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B7; Definitive IC50 using human liver microsomes |
Induction Assays: | |
|
CYP1A2, CYP2B6, CYP3A4 message RNA assay following 24 hour treatment |
|
CYP3A4, CYP2B6, CYP1A2, CYP2C8, CYP2C9, CYP2C19 mRNA, 48 or 72 hour treatment with basic DDI modeling (± CYP activity evaluation) |
Reaction Phenotyping Assays: | |
|
Estimate CYP vs. non-CYP mediated fraction of metabolism |
|
Combination of rCYPs to predict HLM fm,CYP using RAF and/or chemical inhibitors |
|
Combination of rCYPs and/or chemical inhibitors |
|
Combination of rCYPs and/or chemical inhibitors (ketoconazole and CYP3cide) Human cytosol or hepatocytes ±Hydralazine (AO inhibitor) |
Other Assays: | |
|
Plasma, microsomes, HSA, AAG; Species selectable; human clinical plasma |
|
Human |
Bundled IND-Enabling Assays: | |
|
HLMs and human hepatocytes; Assays meet regulatory guidelines for IND |
Metabolite Profiling and Identification Discovery Services | |
---|---|
Discovery to Regulatory Phase Assays | Details (Waters Synapt G2-S and Thermo OrbiTrap and Q-Exactive HRMS) |
Metabolite Profiling and Identification: Microsomes and Hepatocytes | Species selectable; S9, cytosol, or hepatocyte coculture systems available |
P450 Reaction Phenotyping: Metabolite Formation | Microsomes with inhibitors for CYP1A2, CYP2C9, CYP2D6, CYP3A |
Metabolite Profiling and Identification: In Vivo Services | Plasma, urine, bile, feces, and/or tissue homogenate; Species selectable |
Metabolite Profiling and Identification: Exploratory Profiling | Exploratory assessment using unlabeled drug; Preclinical or clinical samples |
Metabolite Profiling and Identification: Radioprofiling and MetID | Preclinical or clinical samples; Typically plasma, urine, bile, and/or feces |
Reactive Intermediate Screen: Glutathione or Cyanide Trapping Agent | Microsomes; Species selectable |
Reactive Intermediate Screen: Covalent Binding | Radiolabel covalent binding in microsomes or hepatocytes, species selectable |
Q2 Solutions operates one of the world’s largest and most respected bioanalytical and ADME laboratory networks. From our global locations, we serve many of the largest pharmaceutical, specialty pharmaceutical and biotechnology companies in North America, South America, Europe and Asia. Our highly trained scientists utilize a range of leading-edge technology, automation and state-of-the-art techniques.
Q2 Solutions offers tailored and comprehensive small molecule bioanalytical and ADME laboratory services. We combine scientific excellence, high-quality project management, and outstanding delivery...
Analysis of a polydisperse heparin analog therapeutic (CX-01, Dociparstat) was conducted in human plasma by signature disaccharide (NS6S) analysis, with NS6S being unique to CX-01 in native human...
In this podcast Barry Jones (Director, LC–MS Biologics and Biomarkers at Q² Solutions) and Adriane Spytko (Manager, LC–MS Biologics at Q² Solutions; both NY, USA) discuss hybrid assays using both...